AstraZeneca may have "included outdated information" in COVID-19 vaccine trial report, U.S. says

AstraZeneca may have used "outdated information" when it released data from a late-stage trial of its COVID-19 vaccine early Monday, federal officials say. The Data and Safety Monitoring Board (DSMB) said late in the day it "was concerned" about the information the British drug maker made public about the trial of the vaccine it developed along with Oxford University.

The National Institute of Allergy and Infectious Diseases (NIAID) said "The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible." AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could have helped rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.